About Icosavax Company
Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses on developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA.
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday. Shares of Ross Stores, Inc. (NASDAQ:ROST) surged during Friday's session as the company reported upbeat results fo
Guggenheim Initiates Coverage On Icosavax With Buy Rating, Announces Price Target of $28
Guggenheim analyst Seamus Fernandez initiates coverage on Icosavax with a Buy rating and announces Price Target of $28.
Icosavax Insiders Forfeit On 41% Gains After Selling Stock
While Icosavax, Inc. (NASDAQ:ICVX) shareholders have had a good week with the stock up 41%, insiders can't say the same having sold stock over the past year. The value of their investment would have